Inari Medical Q2 EPS Forecast Decreased by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Leerink Partnrs lowered their Q2 2025 earnings estimates for Inari Medical in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.01) per share for the quarter, down from their previous estimate of $0.03. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.70) per share. Leerink Partnrs also issued estimates for Inari Medical’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.02 EPS, FY2027 earnings at $0.57 EPS and FY2028 earnings at $1.01 EPS.

Inari Medical (NASDAQ:NARI) last released its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million. Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%.

A number of other brokerages also recently commented on NARI. Piper Sandler reissued a “neutral” rating and set a $50.00 price objective on shares of Inari Medical in a research report on Monday, August 26th. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Canaccord Genuity Group increased their price objective on shares of Inari Medical from $55.00 to $71.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a research report on Wednesday, October 9th. Finally, Truist Financial lowered their target price on shares of Inari Medical from $55.00 to $46.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Inari Medical has an average rating of “Hold” and a consensus target price of $57.44.

Inari Medical Price Performance

NARI opened at $44.23 on Thursday. The business has a fifty day moving average price of $44.20 and a 200 day moving average price of $45.85. Inari Medical has a 12 month low of $36.73 and a 12 month high of $67.13. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -108.78 and a beta of 1.00.

Institutional Investors Weigh In On Inari Medical

Several hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its position in Inari Medical by 113.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares during the period. Armistice Capital LLC increased its holdings in shares of Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after purchasing an additional 786,501 shares during the period. Vanguard Group Inc. raised its stake in shares of Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock worth $268,681,000 after purchasing an additional 561,562 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after purchasing an additional 364,983 shares during the period. Finally, First Light Asset Management LLC grew its position in Inari Medical by 120.8% in the 2nd quarter. First Light Asset Management LLC now owns 472,384 shares of the company’s stock valued at $22,745,000 after buying an additional 258,444 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the sale, the director now owns 643,296 shares in the company, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $55.23, for a total transaction of $165,690.00. Following the completion of the sale, the chief executive officer now owns 455,252 shares of the company’s stock, valued at approximately $25,143,567.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,000 shares of company stock worth $4,175,030 over the last 90 days. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.